Eltrombopag can control ITP long-term, study suggests

“The EXTEND data published in Blood validate [eltrombopag] as an important oral treatment option that, by often increasing platelet counts, significantly decreased bleeding rates and reduced the need for concurrent therapies in certain patients with chronic/persistent immune thrombocytopenia,” said study author James Bussel, MD, of Weill Cornell Medicine in New York, New York.

“With this information, physicians can better optimize long-term disease management for appropriate patients living with this chronic disease.”